Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

BACKGROUND: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the sign...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Nakano, Kazuhiko, Ohta, Shigeyuki, Komatsu, Kenji, Kubo, Taro, Nukui, Akinori, Suzuki, Kazumi, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2012
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3305626/
https://ncbi.nlm.nih.gov/pubmed/22353627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-12-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi